| Disease | BOSSIBLE ENDOCRINE AND LIPID EFFECTS OF L-ARGININE WERE INVESTIGATED IN A DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CROSSOVER STUDY. ORAL L-ARGININE (9G) OR PLACEBO WAS GIVEN DAILY FOR 1 MO, WITH CROSSOVER TO THE ALTERNATE THERAPY AFTER A 1-MO
WASHOUT PERIOD, TO 10 POSTMENOPAUSAL WOMEN RECEIVING NO ESTROGEN. COMPARED WITH PLACEBO, L-ARGININE INCREASED GROWTH HORMONE BUT HAD NO EFFECT ON INSULIN AND CATECHOLAMINES. TOTAL CHOLESTEROL, TRIGLYCERIDE, APOLIPOPROTEIN E, AND LOW-, VERY-LOW-,
AND HIGH-D. LIPOPROTEIN CHOLESTEROL LEVELS WERE ALSO UNAFFECTED. LIPOPROTEIN(A) MEASURED BY AN IMMUNOTURBIDIMETRIC METHOD WAS INCREASED BY L-ARGININE. AND THE CHANGES IN LIPOPROTEIN(A) LEVELS SIGNIFICANTLY CORRELATED WITH THE RELATIVE INCREASE
IN LIPOPROTEIN(A) LEVELS SIGNIFICANTLY CORRELATED WITH THE RELATIVE INCREASE IN GROWTH HORMONE. HOWEVER, LIPOPROTEIN(A) MEASURED BY AN ELISA FAILED TO DEMONSTRATE SIGNIFICANT CHANGES. |